Weight loss jabs improve heart failure symptoms in obese patients – study

Semaglutide not only helped patients in the trial lose weight and eased heart failure symptoms, but also improved their tolerance for exercise (PA)

Weight loss jabs could improve the symptoms of heart failure in obese patients, a new study has found, allowing them to exercise for longer as well as lose weight.

US researchers explored the use of semaglutide – which is sold under the brand names Ozempic, Wegovy and Rybelsus – to treat overweight people with a condition called heart failure with preserved ejection fraction (HFpEF).